Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.…
Integra LifeSciences (IART) Stock Could Be A Bargain Based On Cash Flow
Integra LifeSciences Holdings (NASDAQ: IART) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 4,427 employees.
The shares were at 13.25 USD on 20 November 2026, up 10.0% over 52 weeks. Its 52-week range is 8.700 USD to 20.49 USD: the price is 35.3% below the high and 52.3% above the low.
At a market capitalisation of 1.03B USD, it trades at 77.9 times trailing earnings and 5.6 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a premium of 205% for IART.
Integra LifeSciences Holdings reports return on equity of -49.5%, an operating margin of 9.9% and revenue up 2.3% year over year.
Its debt exceeds its cash by 1.69B USD, a debt-to-equity ratio of 1.95. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 9 analysts cover the stock, with an average rating of Hold; their mean price target of 15.67 USD is 18.2% above the current price. The next earnings report is expected on 25 February 2027.